1. Ganafa AA, Walton M, Eatman D et al.  Amlodipine attenuates oxidative stress-induced hypertension. Am J Hypertens 2004; 17 (9): 743–8.
2. Donati L, Buhler FR, Beretta-Piccoli C, Kusch F et al. Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. Clin Pharmacol Ther 1992; 52 (1): 50–9.
3. Leenen FH. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. Am J Hypertens 1996; 9 (10 Pt 2): 97S–104.
4. Williams DM et al.  Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988; 28 (11): 990–8.
5. Fukuda M, Masuda T, Ogura MN et al. Influence of nifedipine coat-core and amlodipine on systemic arterial stiffness modulated by sympathetic and parasympathetic activity in hypertensive patients. Hypertens Res 2009; 32 (5): 392–8.
6. Ткачева О.Н., Барабашкина А.В., Новикова И.М. и др. Изучение эффектов комбинации рамиприла и амлодипина у пациентов с артериальной гипертензией и сахарным диабетом 2-го типа. Кардиология. 2009; 5: 40–7.
7. Antonopoulos S, Kokkoris S, Gerakari S et al. Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension. Angiology 2008; 59 (2): 230–5.
8. Чазова И.Е., Ратова Л.Г. Антагонисты кальция в лечении артериальной гипертонии (исследование ЭТНА). Системные гипертензии. 2005; 1: 25–8.
9. Чазова И.Е., Ратова Л.Г., Галявич А.С. и др. Лечение артериальной гипертонии у больных с метаболическим синдромом. Системные гипертензии. 2008; 1: 39–43.
10. Zacharieva S, Shigarminova R, Nachev E et al. Ambulatory blood pressure monitoring and active renin in menopausal women treated with amlodipine and hormone replacement therapy. Gynecol Endocrinol 2004; 19 (1): 26–32.
11. Чазова И.Е., Ратова Л.Г. При всем богатстве выбора другой альтернативы нет. Исследование ЭТНА Плюс (ЭТНА в жизни врача поликлиники). Системные гипертензии. 2008; 2: 35–9.
12.Чазова И.Е, Ратова Л.Г. и др. Эффективность антигипертензивной терапии у больных артериальной гипертонией в зависимости от риска сердечно-сосудистых осложнений. Кардиоваскулярная терапия и профилактика, 2008; 7(2):78–82.
13. Takase B, Takeishi Y, Hirai T et al. Comparative effects of amlodipine monotherapy therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patient with poorly controlled hypertension. Circ J 2008; 72 (5): 764–9.
14. Littlejohn TW, Majul CR, Olvera R et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of randomized, placebo-controlled, parallel-group, 4x4 factorial study. Postgrad Med 2009; 121 (2): 5–14.
15. Philipp T, Glazer RD, Zhao Y et al. Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. Curr Med Res Opin 2009; 25 (1): 187–93.
16. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417–28.
17. Valcarcel Y, Jimtnez R, Hernandez V et al. Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres. Clin Drug Investig 2006; 26 (3): 125–33.
18. Littlejohn TW, Majul CR, Olvera R et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of randomized, placebo-controlled, parallel-group, 4x4 factorial study. Postgrad Med 2009; 121 (2): 5–14.
19. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91 (3): 698–706.
20. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group/ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
21. Klingbeil AU, Schneider M, Martus P et al.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41–6.
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attck trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attck trial (ALLHAT). JAMA 2002; 288: 2981–97.
23. Терещенко С.Н., Жиров И.В., Успенская О.В. Место амлодипина в лечении ХСН у женщин. Пробл. женск. здор. 2007; 4 (2): 17–23.
24. Walter MF, Jacob RF, Bjork RE et al. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol 2008; 51 (12): 1196–202.
25. Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48 (4): 833–8.
26. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292 (18): 2217–25.
27. Sever PS, Dablof B, Poulter NR et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive petients who have averege or lower-than-averege cholesterol concentrations, in the Anglo-Scandinvium Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
28. Mason RP, Kubant R, Heeba G et al. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res 2008; 25 (8): 1798–806.
29. Koh KK, Han SH, Ahn JY et al. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol 2009; 133 (1): 23–31.
30. Schulman IH, Zachariah M, Raij L. Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005; 17 (4 Suppl.): 40–5.
31. Ostergren J, Poulter NR, Sever PS et al. The Anglo–Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J Hypertens 2008; 26: 2103–11.
32. Cosin Aguilar J, Rodriguez Padial L, Hernandiz Martinez A et al. Cardiovascular risk in diabetes mellitus and hypertension in Spain. The CORONARIA study. Med Clin (Barc) 2006; 127 (4): 126–32.
33. Griffin KA, Bidani AK. Potential risks of calcium channel blockers in chronic kidney disease. Curr Cardiol Rep 2008; 10 (6): 448–55.
34. Wright JTJr, Agodoa L, Contreras G et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162 (14): 1636–43.
35. Ogihara T, Nakao K, Fukui T et al. The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res 2008; 31 (8): 1595–601.
36. Tepel M, Hopfenmueller W, Scholze A et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008; 23 (11): 3605–12.

Н.К.Рунихина1, О.Н.Ткачева2

1 ГОУ ВПО РГМУ,
2 Терапевтическое отделение Научного центра акушерства, гинекологии и перинатологии им В.И.Кулакова Росмедтехнологий, Москва

________________________________________________

N.K. Runikhina1, O.N. Tkacheva2

1 Russian State Medical University,
2 Therapeutic Department, V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Russian Agency for Medical Technologies, Moscow